Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.

Christine Lovly, MD, PhD, associate professor of Medicine in the Division of Hematology and Oncology and Ingram Professor of Cancer Research, is one of two inaugural recipients of the EGFR Resisters/LUNGevity Lung Cancer Research Award.

A gift in memory of music industry executive and community philanthropist Phran Galante will support the work of Christine Lovly, MD, PhD, associate professor of Medicine and Ingram Professor of Cancer Research, to improve targeted therapies for lung cancer.

Christine Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, has been named incoming chair of GO2 Foundation's Scientific Leadership Board (SLB).

Portia Thomas grew up in Doerun, Georgia, a small, rural city named by pioneer hunters as a place with “a perfect doe run,” where the population has hovered around 800 people for the past 30 years. A childhood impression lifted her aspirations beyond her hometown and inspired her to pursue a career as a physician-scientist.

An advocacy group for patients with anaplastic lymphoma kinase positive lung cancer has awarded a $500,000 grant dedicated to overcoming treatment resistance to the cancer.

When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient.